Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Recursion Pharmaceuticals Q3 2026 Results: Net Loss of $119M, Loss Narrows

Recursion Pharmaceuticals reported a net loss of $119.0 million for the third quarter of 2026, an improvement from the $162.3 million loss in the prior year period. Total revenue increased significantly to $18.6 million for the quarter, while the company maintained a strong liquidity position with $549.9 million in cash and cash equivalents as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue18.65.2
Profit before tax-119.0-162.2
Net income-119.0-162.3
EPS (diluted, $ a share)$-0.22$-0.36

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+258.5%
Source

10-Q filed with the SEC, NASDAQ: RXRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Recursion Pharmaceuticals, Inc.: key numbers

Share price
$2.90Close, Nov 16
Market cap
$1.81B
Shares outstanding
622.76MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Recursion Pharmaceuticals, Inc.

All →
5:13 PM ET Form 4
Insider Selling

Recursion Pharmaceuticals Insider Blake Borgeson Sells $155K of Stock

Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals, Inc. at $3.88 a share, worth $155K in total on Nov 3, 2026. Shares held after the trade: 6,068,287 (-0.7%).

Value
$155K
Shares
40,000
Price
$3.88
Holding change
-0.7%
Trade date
Nov 3, 2026
4:33 PM ET 8-K
Financial Results

Recursion Pharmaceuticals Financial Results

Recursion Pharmaceuticals reported Q3 2026 financial results, highlighting clinical data for REC-4881 and REC-1245 and the appointment of Fred Hassan as Chair of the Board. The company extended its cash runway into 2029 following an October follow-on offering and noted that Sanofi has optioned the first development candidate from their collaboration.

Term
Q3 2026

“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients.”

Najat Khan, Ph.D., President and Chief Executive Officer of Recursion
8:47 AM ET 8-K
Capital Raise

Recursion Pharmaceuticals Capital Raise of $200M

Recursion Pharmaceuticals entered into an underwriting agreement to raise approximately $200 million through a public offering of 61,540,000 shares of Class A common stock at $3.25 per share. The company also announced that Sanofi exercised an option for a first-in-class immunology development candidate under their existing collaboration, triggering a $10 million milestone payment. Proceeds from the equity raise are expected to extend the company's cash runway into 2029.

Value
$200M
Counterparty
Leerink Partners LLC
6:09 PM ET Form 4
Insider Selling

Recursion Pharmaceuticals Insider Blake Borgeson Sells $242K of Stock

Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals, Inc. at $4.84 a share, worth $242K in total on Oct 6, 2026. Shares held after the trade: 6,108,287 (-0.8%).

Value
$242K
Shares
50,000
Price
$4.84
Holding change
-0.8%
Trade date
Oct 6, 2026
6:08 PM ET Form 4
Insider Selling

Recursion Pharmaceuticals Insider Robert Hershberg Sells $125K of Stock

Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals, Inc. at $5.00 a share, worth $125K in total on Oct 6, 2026. Shares held after the trade: 162,156 (-13.4%).

Value
$125K
Shares
25,000
Price
$5.00
Holding change
-13.4%
Trade date
Oct 6, 2026
9:05 AM ET 8-K
Licensing Deal

Recursion Pharmaceuticals Licensing Deal with Tempus AI, Inc. Worth $12M

Recursion Pharmaceuticals granted Tempus AI a non-exclusive license to its TxFM RNA sequencing model for use in oncology in exchange for a $12 million license fee. Simultaneously, the parties amended an existing master agreement to extend its term to six years and restructure annual license fees, while Recursion gained access to additional de-identified pathology records.

Value
$12M
Counterparty
Tempus AI, Inc.
Term
2 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.